

# Mitchel Tate

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7861720/publications.pdf>

Version: 2024-02-01

23  
papers

935  
citations

566801

15  
h-index

610482

24  
g-index

26  
all docs

26  
docs citations

26  
times ranked

1631  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Fine-tuning the cardiac O-GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart. <i>Cardiovascular Research</i> , 2022, 118, 212-225.                                       | 1.8 | 47        |
| 2  | Current landscape of preclinical models of diabetic cardiomyopathy. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 940-956.   | 4.0 | 8         |
| 3  | Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy – current and future perspectives. <i>Clinical Science</i> , 2021, 135, 1369-1387.   | 1.8 | 8         |
| 4  | Characterisation of the Myocardial Mitochondria Structural and Functional Phenotype in a Murine Model of Diabetic Cardiomyopathy. <i>Frontiers in Physiology</i> , 2021, 12, 672252.   | 1.3 | 6         |
| 5  | Bone Morphogenetic Protein 7 Gene Delivery Improves Cardiac Structure and Function in a Murine Model of Diabetic Cardiomyopathy. <i>Frontiers in Pharmacology</i> , 2021, 12, 719290.  | 1.6 | 8         |
| 6  | Editorial: Translational Approaches for Targeting Cardiovascular Complications of Diabetes. <i>Frontiers in Pharmacology</i> , 2021, 12, 799020.   | 1.6 | 0         |
| 7  | The Role of Bone Morphogenetic Proteins in Diabetic Complications. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 11-20.   | 2.5 | 17        |
| 8  | Confirmation of the Cardioprotective Effect of MitoGamide in the Diabetic Heart. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 823-834.  | 1.3 | 9         |
| 9  | Gene therapy targeting cardiac phosphoinositide 3-kinase (p110 $\alpha$ ) attenuates cardiac remodeling in type 2 diabetes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2020, 318, H840-H852. | 1.5 | 32        |
| 10 | The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 669-674.   | 1.3 | 15        |
| 11 | Cardioprotective Actions of the Annexin-A1 N-Terminal Peptide, Ac2-26, Against Myocardial Infarction. <i>Frontiers in Pharmacology</i> , 2019, 10, 269.  | 1.6 | 30        |
| 12 | Characterising an Alternative Murine Model of Diabetic Cardiomyopathy. <i>Frontiers in Physiology</i> , 2019, 10, 1395.  | 1.3 | 29        |
| 13 | Recent novel approaches to limit oxidative stress and inflammation in diabetic complications. <i>Clinical and Translational Immunology</i> , 2018, 7, e1016.   | 1.7 | 119       |
| 14 | Oxidative Stress and NLRP3-Inflammasome Activity as Significant Drivers of Diabetic Cardiovascular Complications: Therapeutic Implications. <i>Frontiers in Physiology</i> , 2018, 9, 114.                                   | 1.3 | 150       |
| 15 | Gremlin1 plays a key role in kidney development and renal fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, F1141-F1157.   | 1.3 | 58        |
| 16 | Are targeted therapies for diabetic cardiomyopathy on the horizon?. <i>Clinical Science</i> , 2017, 131, 897-915.  | 1.8 | 83        |
| 17 | Insulin replacement limits progression of diabetic cardiomyopathy in the low-dose streptozotocin-induced diabetic rat. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 423-433.                                    | 0.9 | 35        |
| 18 | The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction. <i>Cardiovascular Diabetology</i> , 2017, 16, 33.  | 2.7 | 80        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Endogenous Annexin-A1 Regulates Haematopoietic Stem Cell Mobilisation and Inflammatory Response Post Myocardial Infarction in Mice In Vivo. <i>Scientific Reports</i> , 2017, 7, 16615.          | 1.6 | 38        |
| 20 | Metabolically-inactive glucagon-like peptide-1(9-36)amide confers selective protective actions against post-myocardial infarction remodelling. <i>Cardiovascular Diabetology</i> , 2016, 15, 65. | 2.7 | 25        |
| 21 | Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages. <i>Basic Research in Cardiology</i> , 2016, 111, 1.          | 2.5 | 57        |
| 22 | Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. <i>British Journal of Pharmacology</i> , 2015, 172, 721-736.   | 2.7 | 21        |
| 23 | Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix. <i>Basic Research in Cardiology</i> , 2015, 110, 20.        | 2.5 | 57        |